APSR2026-493

Yes
Late-Breaking
Submitted
Poster Presentation
 
AP10-014
P14
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1213351-46904-APSR_2026_COPD_Poster_Adobe_Compatible_Logos_431246.pdf
Format: PDF Only
07. COPD
4

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

SUNN REN TEE * HOSPITAL QUEEN ELIZABETH RESPIRATORY DEPARTMENT KOTA KINABALU Malaysia
HEMA YAMINI DEVI A/P RAMARMUTY - HOSPITAL QUEEN ELIZABETH RESPIRATORY DEPARTMENT KOTA KINABALU Malaysia
KUNJI KANNAN A/L SIVARAMAN KANNAN - HOSPITAL QUEEN ELIZABETH RESPIRATORY DEPARTMENT KOTA KINABALU Malaysia
MUHAMMAD HAZMI BIN HAMDAN - HOSPITAL QUEEN ELIZABETH RESPIRATORY DEPARTMENT KOTA KINABALU Malaysia
 
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
SUNN REN
TEE
sunnrentee91@gmail.com
+60183632907
31-40
Malaysia
Original Research
Blood Eosinophil Count and Cardiometabolic Treatment Burden in GOLD B/E COPD: Relationship with Antiplatelet Use, Oral Hypoglycaemic Therapy, and the Influence of Inhaled Corticosteroids
Maximum 25 words
Abstract Content
Blood eosinophil count is an established biomarker in chronic obstructive pulmonary disease (COPD), guiding inhaled corticosteroid (ICS) therapy and reflecting type-2 airway inflammation. Its relationship with cardiometabolic comorbidity is less well defined. We examined associations between eosinophil burden and antiplatelet use, diabetes pharmacotherapy with oral hypoglycaemic agents (OHA)/insulin, and whether ICS exposure influenced diabetes treatment burden in GOLD B/E COPD.
We conducted a cross-sectional real-world study of GOLD B/E COPD patients receiving long-acting bronchodilator therapy (Spiolto, Ultibro, or Anoro). Patients were categorized by eosinophil count, antiplatelet use, and OHA/insulin use. Eosinophil strata were <100, 100-300, 300-500, 500-1000, and >1000 cells/µL. Threshold analyses were performed at ≥300, ≥500, and >1000 cells/µL. Associations were tested using Fisher’s exact test, with odds ratios (ORs) derived from 2×2 comparisons.
Of 205 screened patients, 121 met inclusion criteria. Antiplatelet use across eosinophil strata was 8.3%, 8.3%, 17.1%, 13.5%, and 15.4%, with no overall association (p=0.887). At ≥300 cells/µL, antiplatelet use was numerically higher than at <300 cells/µL, but not significant (OR 1.99, p=0.388). OHA/insulin use across eosinophil strata was 16.7%, 12.5%, 14.3%, 21.6%, and 38.5%, highest in the >1000 cells/µL group. Although the overall association was not significant (p=0.380), threshold analyses showed progressively higher odds of diabetes pharmacotherapy: OR 1.67 at ≥300 cells/µL, OR 2.14 at ≥500 cells/µL, and OR 3.13 at >1000 cells/µL (p=0.071). ICS use was not associated with OHA/insulin therapy (20.0% vs 18.6%; OR 1.09, p=1.00).
In GOLD B/E COPD, eosinophil burden was not associated with antiplatelet use, but higher eosinophil levels showed progressively greater odds of diabetes pharmacotherapy, strongest at >1000 cells/µL, independent of ICS exposure.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
Chronic Obstructive Pulmonary Disease (COPD), Blood Eosinophils, Diabetes Mellitus
maximum 3 keywords and no abbreviations, separated by commas
The authors acknowledge the contribution of the clinical staff and colleagues who assisted in patient care and data collection for this study.
309